TRIM 50-60% OF TMO POSITION ON PUSHES ABOVE $665; STOP LOSS AT $625-$630; HOLD 40-50% CORE; DO NOT ADD AT $665; RELOAD ZONES AT $580-$605 OR ABOVE $680 WITH VOLUME CONFIRMATION

• FCF dropped 13.5% year over year; net debt exploded by $9 billion in six months; leverage rose from 2.56x to 3.28x net debt to EBITDA
• TMO trading at 24.3x EV/EBITDA versus historical band of 18-22x; street median target at $645 below spot; forward P/E at 24.2x
• Current price $665 requires only 5% additional upside to reach $700 target; upper Bollinger band at $668.36, recent high at $671; breakout probability less than 10%
• Realistic downside distribution is 10-20% drawdown with high probability; bear case at $550 (17% down), 50 SMA at $595 (10.5% down), 200 SMA at $537 (19% down)
• Recommends trimming 50-60% of TMO exposure on any push above $665 (vs aggressive analyst's 25-35% trim)
• Stop loss tightened to $625-$630, just below 10 EMA and Bollinger mid band (vs trader's $596 stop which is nearly 11% below current levels)
• For remaining 40-50% position, do not add at $665 regardless of long-term thesis; asymmetric re-entry point is $585-$605, not $665
• Already banked 36.4% gain should be protected by redeploying trimmed capital at better entry points
• Considers neutral analyst's hold-everything stance as most dangerous: 'it assumes time is free' when carrying full position into binary earnings event with hostile macro backdrop
• Core position should be maintained only because TMO's franchise is 'genuinely best in class' with long-term value from Mayo partnership and AI healthcare infrastructure narrative

→ vs aggressive: Trimming only 25-35% leaves 65-75% of position vulnerable to the asymmetric downside already correctly identified in the evidence; the conclusion 'doesn't follow from the evidence'

→ vs aggressive: The 'asymmetric upside' framing is backwards: realistic upside is only 5% with low probability versus 10-20% downside with high probability, making it asymmetric to the downside

→ vs neutral: Hold-everything stance is 'the most dangerous' because it assumes time is free when carrying full position into binary earnings event with deteriorating fundamentals and hostile macro; this is 'complacent, not neutral'

Trim 35 to 45 percent of position on push above $665 in 2–3 tranches; tighten stop to $612–$615; hold residual 55–65 percent core position through earnings; re-enter at $585–$605 on weakness or above $668 on breakout confirmation

• Trim 35–45% on move above $665, executed in 2–3 tranches, leaving residual at 55–65% of original weight
• Tighten stop from $596 to $612–$615, below Bollinger lower band zone but above noise triggers
• Re-entry zones: $585–$605 on structural weakness below 50 SMA, or daily close above $668.36 Bollinger upper band with volume confirmation and 3–5 session holding pattern
• Forward P/E of 24.2x prices in 48% EPS growth; Olink integration in run rate with Q2 margin recovery to 18.2%
• Net debt of $38.5B with net debt/EBITDA of 3.28x; investment grade with $6.2B TTM free cash flow and $3B annual buyback program
• Mayo Clinic Precure partnership positions TMO as infrastructure layer for population-scale multi-omic data
• ATR is $15.37; proposed stop at $612–$615 represents approximately 4.7–4.9 ATR
• Q2 revenue up 10.5% YoY; CEO Marc Casper commentary on 2026 being outstanding year backed by data
• Beta of 0.85 in defensive sector with robust dividend and capital return program
• Conservative analyst's $625 stop only 40 points below spot (2.6 ATR) will trigger on routine 5–7% pullback noise
• Neither aggressive nor conservative frameworks account for TMO as long-term compounder with strategic moat

→ vs aggressive: $596 stop is a relic from initial trade placement; 11% below spot gives back nearly entire two-month gain and is miscalibrated given flagged asymmetric downside distribution; 7–10% pre-earnings shakeout would trigger trim but leave residual deep in drawdown

→ vs aggressive: Framing 25–35% trim as aggressive is intellectually dishonest; that is a hedge, not an aggressive position

→ vs aggressive: Dismissing bullish structure too quickly; 10 EMA, 50 SMA, and 200 SMA all stacked bullishly and rising; MACD expanding with positive histogram; no bearish RSI divergence; August 26 RSI peak of 75.34 was followed by higher high despite 4.5% pullback

→ vs aggressive: Using four-day pullback as evidence of top while ignoring multi-month trajectory is confirmation bias in reverse

→ vs aggressive: Underweighting quality of franchise and demand recovery; CEO commentary is backed by real Q2 numbers, not narrative

→ vs conservative: $625–$630 stop overshoots; puts stop just above 10 EMA at $642 and barely below Bollinger mid-band at $626; will get stopped out on normal 5–7% pullback that is routine volatility for TMO

→ vs conservative: Treating TMO like SaaS stock with 30% revenue sensitivity to rate cuts; TMO has low cyclicality, sticky customer relationships, recurring service revenue, and defensiveness profile

→ vs conservative: Overstating credit risk; $38.5B net debt largely from Q1 2026 acquisitions already deployed; 3.28x leverage is elevated but investment grade with $6.2B TTM FCF

→ vs conservative: 96% no-cut probability on Polymarket does not account for TMO's defensive characteristics; high-duration speculative growth gets crushed first in rate-backup regime, not TMO

→ vs conservative: Treating TMO as tactical trade to time binary event perfectly; should account for long-term compounding thesis